Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Selective Catalytic Hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN108689910B reveals a novel catalytic hydrogenation route for 1-cyclohexene-1,2-dicarboximide, offering superior purity and streamlined supply chain solutions for global manufacturers.
Patent CN102295531B details a novel M2 catalyst method for high-purity citronellol. Achieve superior selectivity and cost reduction in flavor manufacturing.
Advanced synthesis of high-purity bicyclic amino acid intermediates via novel stereoselective routes. Reduces impurities and enhances supply chain reliability for API manufacturing.
Patent CN100564360C details a novel aqueous cyanation and selective hydrogenation route for high-purity pyridine intermediates, offering significant cost reduction and supply chain reliability for fungicide manufacturing.
Patent CN112441966A details a novel route converting 2,3,6-trichloro-5-trifluoromethylpyridine waste into high-purity 2-chloro-3-trifluoromethylpyridine, offering significant cost and supply chain advantages.
Patent CN101712668B details a scalable synthetic route for apigenin glycosides, offering high purity and yield compared to plant extraction for reliable supply.
Patent CN113024624A details a novel 8-step synthesis of deoxycholic acid from cholic acid, offering significant cost reduction and scalable manufacturing for pharmaceutical applications.
Patent CN115536720A details a novel chemical synthesis for cholic acid intermediate A8, offering a virus-free, plant-based alternative to animal extraction with scalable manufacturing potential.
Patent CN100355732C reveals a novel catalytic hydrogenation route for 2-chloro-5-fluoro-nicotinic acid, offering superior yield and supply chain stability for pharmaceutical manufacturers.
Patent CN117003642A reveals a novel route for Ensitrelvir intermediates. Achieve high purity and reduced costs with scalable pharmaceutical intermediate manufacturing strategies.
Solve supply chain risks and low yields in anticancer intermediate production. Discover a 4-step, 84% yield route using common raw materials. Contact us for scalable CDMO solutions.